Table 2 Age-eligible MV and Pentavalent3 coverage and changes by phases (before the EVD outbreak, during the EVD outbreak, and following the catch-up campaign)
Phase 1 | Phase 2 | Changes (Phase 2–1) (95% CI) | Phase 3 | Changes (Phase 3–2) (95% CI) | |
|---|---|---|---|---|---|
No. of vaccinated/ No. of investigated (Coverage 95% CI) | No. of vaccinated/ No. of investigated (Coverage 95% CI) | No. of vaccinated/ No. of investigated (Coverage 95% CI) | |||
MV | |||||
Jui | 32/37 (86.5, 75.5–97.5) | 8/13 (61.5, 35.1–88.0) | −25.0 (−50.2, 0.3) | 8/13 (61.5, 35.1–88.0) | 0.0 (−37.4, 37.4) |
Grafton | 15/28 (53.6, 35.1–72.0) | 1/9 (11.1, 0–31.6) | −42.5 (−79.7, −5.3) | 4/10 (40.0, 9.6–70.4) | 28.9 (−10.8, 68.5) |
Kossoh town | 20/29 (69.0, 52.1–85.8) | 7/13 (53.9, 26.8–81.0) | −15.1 (−46.5, −16.2) | 9/14 (64.3, 39.2–89.4) | 10.4 (−26.7, 47.5) |
Subtotal | 67/94 (71.3, 62.1–80.4) | 16/35 (45.7, 29.2–62.2) | −25.6 (−44.2, −7.0) | 21/37 (56.8, 40.8–72.7) | 11.1 (−12.1, 34.1) |
Pentavalent3 | |||||
Jui | 39/45 (86.7, 76.7–96.6) | 6/9 (66.7, 35.9–97.5) | −20.0 (−46.7, 6.7) | 7/10 (70.0, 41.6–98.4) | 3.3 (−38.5, 45.2) |
Grafton | 22/35 (62.9, 46.9–78.9) | 1/10 (10.0, 0–28.6) | −52.9 (−88.0, −17.7) | 3/10 (30.0, 1.6–58.4) | 20.0 (−15.1, 55.1) |
Kossoh town | 34/39 (87.2, 76.7–97.7) | 5/11 (45.5, 16.0–74.9) | −41.7 (−69.4, −14.0) | 8/12 (66.7, 40.0–93.3) | 21.2 (−19.3, 61.8) |
Subtotal | 95/119 (79.8, 72.6–87.0) | 12/30 (40.0, 22.5–57.5) | −39.8 (−57.8, −21.8) | 18/32 (56.3, 39.1–73.4) | 16.3 (−8.6, 41.1) |